
Dr Reddy's Laboratories Ltd. announced on Thursday, November 5, that Brazil's National Health Surveillance Agency (ANVISA) has granted marketing authorization for a generic semaglutide injection. According to the company's statement, the product will be available as a pre-filled, multi-dose injectable pen in two presentations - 2mg/1.5ml and 4mg/3ml - for once-a-week dosing. The approval represents a significant milestone for the Hyderabad-based pharmaceutical company's global semaglutide strategy, expanding its presence in Brazil, one of the key markets in Latin America. This medication is intended for adults with type 2 diabetes mellitus whose condition is inadequately controlled by diet and exercise alone. Notably, this approval comes after ANVISA had denied approval for the drug in April, with the company's application failing to meet all regulatory requirements at that time.
The semaglutide injection is designed for the treatment of adults with insufficiently controlled type 2 diabetes mellitus, as an adjunct to diet and exercise. The product will be available as a pre-filled, multi-dose injectable pen in two presentations - 2mg/1.5ml and 4mg/3ml - for once-a-week dosing. The semaglutide injection is used either as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, or in addition to other medicinal products for the treatment of diabetes mellitus. Dr. Reddy's entry into this market aims to address the substantial need for effective diabetes management solutions in Brazil by providing a cost-effective alternative to existing treatments.
According to the company's statement, Brazil has 16.6 million adults in the 20 to 79 years range living with diabetes and the country globally ranks sixth in terms of adults living with diabetes. The semaglutide market for diabetes is estimated at approximately $244.6 million in Brazil. MV Ramana, CEO, Global Generics, Dr Reddy's Laboratories, stated that the company plans to launch semaglutide in Brazil with Aché, with the approval building on the company's broader semaglutide strategy. The substantial treatment need in Brazil makes it an important market for expanding access to semaglutide treatment options, with the company's focus on making this medication more accessible to patients in need.
Dr Reddy's has been banking on generic versions of semaglutide, the active ingredient in Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss drug Wegovy, as a major growth driver in India and a few global markets. The company had recalled batches of generic semaglutide in Canada earlier this year after it found an impurity in the active ingredient. It will relaunch the drug in Canada this quarter and is targeting launches in Latin America and Africa in the coming months. As reported by Business Standard, the company's focus with semaglutide is to expand access to this treatment option across markets where the patient need is significant, with Brazil being an important part of that journey.